Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST life insurance company's accumulated premium income from January to August reached approximately 29.03 billion yuan.
Tianmao Group (000627.SZ) has announced that its subsidiary, Guohua Life Insurance Co., Ltd., a company controlled by the company, will follow according to...
Hubei Biocause Pharmaceutical (000627.SZ) announces that its controlling subsidiary, CHINA BEST Life Insurance Co., Ltd., is proceeding with business development in accordance with the overall strategy of "firmly transitioning for development, highlighting value growth, comprehensively improving capabilities, and moving towards a mature insurance enterprise". The company is focusing on value-based business, continuously promoting business structure optimization. From January 1, 2024 to August 31, 2024, the accumulated original insurance premium income is approximately 29.03 billion yuan.
Related Articles
HK Bull/Bear Outstanding Qty Ratio(54:46) | January 3rd
Berkshire Hathaway (BRK.A.US, BRK.B.US) officially enters the "post-Buffett era", market focuses on Abel's performance after taking over.
Overnight US stocks | On the first trading day of the 26th year, the three major indices rose and fell unevenly. Tesla, Inc. (TSLA.US) fell for seven consecutive days.
HK Bull/Bear Outstanding Qty Ratio(54:46) | January 3rd
Berkshire Hathaway (BRK.A.US, BRK.B.US) officially enters the "post-Buffett era", market focuses on Abel's performance after taking over.
Overnight US stocks | On the first trading day of the 26th year, the three major indices rose and fell unevenly. Tesla, Inc. (TSLA.US) fell for seven consecutive days.
